NYSE: ANRO
Alto Neuroscience, Inc.
Healthcare · Biotechnology
Market Cap
$729.96M
52w High
$28.44
52w Low
$2.15
P/E
-10.11
Volume
374.61K
Outstanding Shares
31.95M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 864.14% over the last year. Free cash flow declined 14.56% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
7
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 19, 2026
Q3 FY26 · EPS est -$0.62 · Revenue est —
View